Latest News and Press Releases

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and...

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months...